Cancer treatment is investigated worldwide using various resources. e molecular pathogenesis of cancer gives us advantages to nd potential anticancer drugs. Scientists are now more prone to develop drugs that bind in a speci c site to decrease the potential side e ects and prolong the cure.
e treatment of cancer can be divided into di erent categories. Surgery is the rst line treatment for solid tumors and the early stages of cancer.
Even benign growths can be removed by this technique (Abelo , 2008; Edmund et al., 2007) . e goal of radiation treatment is the (Tartour et al., 1999; Numasaki et al., 2003; Kato et al., 2001) . IL-17 is the core factor to promote tumor development, tumor growth and angiogenesis. us, this molecular targeted drug can be investigated to cure cancer. Ligand mediated drugs can be designed to target this IL-17 protein with very few side e ect.
Potential next generation drug target in cancer
A pro-in ammatory cytokine is produced by activated CD4+ 
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Significance | Despite the use of IL17A in the rheumatoid arthritis, it is not used as therapeutic target in cancer. Targeting IL17A can control the hundreds of the bio-markers in cancer.
tory cytokines have an important anti-tumorigenic role and in the growth and spread of the malignancy (Coussens and Werb, 2002; Wilson and Balkwill, 2002) . Furthermore, Interleukin-1 (IL-1) and IL-6 induce proliferation and prolonged cell survival (Miki et al., 2002; Lus and Donovan, 1999; Ito and and Miki, 1999 ). e pro-in ammatory cytokine IL-17 is produced by activated CD4 T-cells and CD8 T-cells (in human) (Yao et al., 1995; Shin et al., 1999) . IL-17 and and IL-6 promote the tumourigenicity of human cervical cancer, ovarian cancers and promotes tumour angiogenesis due to the enhancement of vascular endothelial growth factor (VEGF) (Tartour et al., 1999; Pages et al., 1999; Kato et al., 2001; Numasaki et al., 2003; Takahashi et al., 2005; Wong et al., 1999) . ere is a correlation between vascularity and invasive behaviour in CRC (Choi et al., 1998) . IL-1‚ and IL-6 have been associated with colorectal cancer (Komoda et al., 1998) .
IL-17 induces IL-1 from macrophages to stimulate epithelial and broblastic cells to secrete IL-6 (Jovanovic et al., 1998; Fossiez et al., 1996) . IL-17 is demonstrated to increase the production of active metalloproteinase MMP-9 (Prause et al., 2004) . e role of metalloproteinases in the progression of human malignancies is well documented in numerous reports (Matrisian et al., 1994; Roeb et al., 2001) . [To be continued...] Acknowledgment e editor would like to express his gratitude to his editorial fellows.
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